Biotechnology company, Genzyme Corp. (GENZ) announced Thursday, that it has received a June 17, 2010 PDUFA date or Action Date - the date by which the FDA will decide upon a filing for approval for its Biologics License Application for Lumizyme seeking approval for the therapy produced at the 4000 L scale. The FDA has classified the resubmission as a class 2 complete response, which carries a six-month review timeframe.
Genzyme last month reopened enrollment in the Alglucosidase Alfa Temporary Access Program or ATAP, a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme. The company has provided therapy free of charge to approximately 170 patients since 2007, and is working with the 81 active study sites in the U.S. to enroll additional patients into this program.
The ATAP program will remain open until commercial approval of Lumizyme. The 4000 L-scale Lumizyme is produced at Genzyme's manufacturing plant in Geel, Belgium.
Lumizyme is marketed outside of the United States as Myozyme, and is commercially approved for the treatment of Pompe disease in around 40 countries worldwide.
The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, as well as cardiovascular and neurodegenerative diseases, and other areas of health care.
GENZ is traded at $54.34 down $0.51 or 0.93% on a volume of 1.786 million shares on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.